Guse Kyle
CIK: 0001566618
Associated companies
Transaction History
| CNSY | ▲ Buy | Option Exercise | 921 | $0 | 10/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 922 | $0 | 7/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 921 | $0 | 10/1/2026 | View on chart |
| CNSY | ▲ Buy | Option Exercise | 922 | $0 | 7/1/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.